Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

91.13 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
NYSE:NVO stands out as a growth opportunity that won't break the bank.
NYSE:NVO, a growth stock which is not overvalued. 
Via Chartmill
Which High-Profile Stock-Split Stock Is the Cheapest? Get Ready to Be Shocked...
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's one clear-cut stock-split stock that's notably cheaper than the rest. 
Via The Motley Fool
WW International Shares Jump On BCBS Michigan's Revised Authorization For Wegovy, Other Weight Loss Drugs
Via Benzinga
Stock Market Falls Into Correction On Hawkish Fed: Weekly Review
Treasury yields surged to long-term highs, while leading stocks buckled. 
Via Investor's Business Daily
Where Will Novo Nordisk Stock Be in 5 Years?
Weight-loss treatments are a big part of Novo Nordisk's business and could be key to its growth for years to come. 
Via The Motley Fool
Don't overlook NYSE:NVO—a stock with solid growth prospects and a reasonable valuation.
In the world of growth stocks, NYSE:NVO shines as a value proposition. 
Via Chartmill
Novo Nordisk Unusual Options Activity For September 21
Via Benzinga
Why Novo Nordisk Stock Dipped Today
Popularity has its downsides. 
Via The Motley Fool
Why Novo Nordisk Stock Was Tumbling on Thursday
A downbeat analyst take resonated with investors. 
Via The Motley Fool
Coca-Cola Short Seller Says Dominance Fizzles In Face Of Bubbly Upstarts, Weight Loss Drugs
Coca-Cola short seller says market dominance is fading to competitors and weight-loss drugs such as Ozempic. 
Via Benzinga
FDA Inspection Turns Up 'Objectionable' Bacteria In Key Novo Nordisk Plant
The company says it has since corrected the issues found in the FDA inspection. 
Via Investor's Business Daily
Exposures Product Safety
Why Novo Nordisk Stock Edged Higher Today
The good news outweighed the bad for the hot drug developer on Hump Day. 
Via The Motley Fool
Ypsomed To Supply Autoinjectors To Novo Nordisk Under Long-Term Agreement
Swiss medical technology company Ypsomed (OTC: YPHDF) announced a long-term supply  
Via Benzinga
Eli Lilly Cracks Down on Counterfeit Mounjaro Wight Loss and Diabetes Drugs, Sues Lawsuit Against Clinics
Eli Lilly And Co (NYSE: LLY) has taken  
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,700 Today
Via Benzinga
Should You Buy Ozempic Maker Novo Nordisk Before Its Stock Split?
The upcoming stock split isn't the main story with this high-flying pharma stock. 
Via The Motley Fool
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories
Bloomberg 
Via Benzinga
Novo Nordisk Partners With South Africa-Based Aspen To Supply Insulin For African Countries
Novo Nordisk A/S (NYSE: NVO) announced a new partnership with& 
Via Benzinga
Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?
Eli Lilly & Co. stock has been on a tear, trading up 57.7% year-to-date on the strength of its industry-leading medications and highly-anticipated pipeline 
Via MarketBeat
Single Bitcoin In 2021 Was Enough To Purchase A Tesla Model Y, Softbank Explores Investing In OpenAI, Ford Faces UAW Strike In US, Canada: Today's Top Stories
Benzinga 
Via Benzinga
Novo Nordisk Dives After FDA Reportedly Finds 'Objectionable' Conditions At A Key Wegovy Plant
The FDA reportedly inspected a Novo facility charged with making diabetes and weight-loss drugs. 
Via Investor's Business Daily
Exposures Product Safety
Quality Control Issues at Novo Nordisk's Clayton Plant - Key Site for Weight-Loss, Diabetes Drug Production
The FDA has reportedly issued a report detailing quality control lapses at Novo Nordisk A/S's (NYSE: NVO) Clayton, North Carolina plant. 
Via Benzinga
Exposures Product Safety
3 Phenomenal Stock-Split Stocks You Should Be Buying Now
These three fantastic stock-split stocks are stocks investors should be buying in the wake of last year's wave of splits. 
Via InvestorPlace
3 Stock-Split Stocks Billionaire Investors Can't Stop Buying
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three highfliers Wall Street's top managers are piling into. 
Via The Motley Fool
Yet Again, Ozempic Could Soon Get Even Better for Novo Nordisk Stock
The results of a small new study could open the door to yet another market. 
Via The Motley Fool
The 7 Most Undervalued Cathie Wood Stocks to Buy in September 2023
Elevate your portfolio with these Cathie Wood's undervalued stocks brimming with robust long-term growth potential 
Via InvestorPlace
3 (Bad) Reasons to Avoid or Sell Novo Nordisk Stock
The rhetoric surrounding popular businesses isn't always good advice. 
Via The Motley Fool
3 Top Healthcare Stocks Defying the Bear Market
Revenue at all three companies improved last quarter, and their share prices have followed suit. 
Via The Motley Fool
This Stock Is Lifting an Entire Country's Economy -- Is It a Buy?
The drugmaker is clearly firing on all cylinders. 
Via The Motley Fool
Topics Economy
Exposures Economy
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.